Blood DiseaseNCT00005438
Neuropsychological Studies of Children With Sickle Cell
An observational study of Blood Disease and Anemia, Sickle Cell, run by National Heart, Lung, and Blood Institute (NHLBI).
Trial summary
To identify those factors that contributed to cognitive deficiencies in children with sickle cell disease (SCD) who had not demonstrated any overt or clinically apparent neurological abnormalities. Read more about this study
- Who is it for?
- Ages Up to 100 years, men only
- Conditions the study is for
- Blood Disease, Anemia, Sickle Cell, Neurologic Manifestations
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Feb 1993to Jan 1998
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 100 years
- Men only
- No healthy volunteers
- Child, Adult, Older adult
No eligibility criteria
About this study
To identify those factors that contributed to cognitive deficiencies in children with sickle cell disease (SCD) who had not demonstrated any overt or clinically apparent neurological abnormalities.
Read the detailed description
BACKGROUND:
Although there has been evidence for a relationship between sickle cell disease and pathology of the central nervous system since 1923, there has been a tendency in the psychosocial literature to attribute any decreased cognitive performance in children with sickle cell disease to illness-related or demographic factors (e.g., school absenteeism, socioeconomic status) rather than to the disease process of SCD (e.g., chronic microvascular insults to the central nervous system). Cerebral infarction is the most common neurological complication that occurs in children with SCD, but clinically it presents itself in only five to ten percent of children with this chronic illness. The majority of children with SCD are also at high risk of demonstrating learning deficits and poor school performance. Studies suggest that a significant number of children with SCD who do not display any overt symptomatology of neurologic disease often exhibit decreased academic performance in comparison to healthy matched peers. Given the pathophysiology of SCD, it is reasonable to hypothesize that the insidious onset of impaired cognitive functioning is the result of multiple microinfarcts, small hemorrhages, and progressive vascular disease. Therefore, the disease process of SCD could be a primary contributing factor to long-term decreased cognitive performance often demonstrated by the adult SCD population. It is thus critical to examine young children with SCD who do not exhibit gross manifestations of neurological insult in order to determine the cause of these cognitive deficits.
DESIGN NARRATIVE:
A total of 60 infants and toddlers with SCD and 60 matched normally-developing peers between the ages of birth and three years served as subjects in a five-year longitudinal design in order to permit between-group comparisons. Subjects were assessed at regularly scheduled intervals with a variety of developmental (e.g., Bayley), cognitive (e.g., Stanford-Binet), neuropsychological (e.g., Purdue Pegboard), family functioning, and physiological indices in order to delineate those factors in the SCD group that were associated with decreased cognitive and academic performance. A unique and important feature of this research was the inclusion of magnetic resonance imaging technology. These techniques made it possible to study in a comprehensive and componential manner the neuroanatomical effects of SCD instead of relying on any single instrument or assessment to document this phenomenon. Goals of this study included the identification of: (a) specific areas of learning deficiencies in children with SCD; (b) the period in which these deficiencies began to occur; and (c) the relationship between types of learning deficits and various outcome measures. In sum, this study helped to determine how these factors interacted and changed over time as the child with SCD matured, the disease fluctuated, and the family and/or the environmental context changed in relation to cognitive development.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
- Medical subject headings
- Hematologic Diseases, Anemia, Sickle Cell, Neurologic Manifestations
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2000 (estimated)
- Study startFeb 1993
- Study completionJan 1998
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood DiseaseStudies of the same condition, open and under way.
- More trials run by National Heart, Lung, and Blood Institute (NHLBI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00005438
- Sponsor's protocol ID
- 4366
- Other IDs
- R29HL047872
- Status last verified
- Nov 2001
- First submitted
- 25 May 2000
- Last updated
- 13 May 2016
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neuropsychological Studies of Children With Sickle Cell
- ClinicalTrials.gov ID
- NCT00005438
- Acronym / sponsor ID
- 4366
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)US National Institutes of Health
- Study start
- Feb 1993
- Study completion
- Jan 1998 (actual)
- First posted
- 26 May 2000 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To identify those factors that contributed to cognitive deficiencies in children with sickle cell disease (SCD) who had not demonstrated any overt or clinically apparent neurological abnormalities.
Detailed description
BACKGROUND:
Although there has been evidence for a relationship between sickle cell disease and pathology of the central nervous system since 1923, there has been a tendency in the psychosocial literature to attribute any decreased cognitive performance in children with sickle cell disease to illness-related or demographic factors (e.g., school absenteeism, socioeconomic status) rather than to the disease process of SCD (e.g., chronic microvascular insults to the central nervous system). Cerebral infarction is the most common neurological complication that occurs in children with SCD, but clinically it presents itself in only five to ten percent of children with this chronic illness. The majority of children with SCD are also at high risk of demonstrating learning deficits and poor school performance. Studies suggest that a significant number of children with SCD who do not display any overt symptomatology of neurologic disease often exhibit decreased academic performance in comparison to healthy matched peers. Given the pathophysiology of SCD, it is reasonable to hypothesize that the insidious onset of impaired cognitive functioning is the result of multiple microinfarcts, small hemorrhages, and progressive vascular disease. Therefore, the disease process of SCD could be a primary contributing factor to long-term decreased cognitive performance often demonstrated by the adult SCD population. It is thus critical to examine young children with SCD who do not exhibit gross manifestations of neurological insult in order to determine the cause of these cognitive deficits.
DESIGN NARRATIVE:
A total of 60 infants and toddlers with SCD and 60 matched normally-developing peers between the ages of birth and three years served as subjects in a five-year longitudinal design in order to permit between-group comparisons. Subjects were assessed at regularly scheduled intervals with a variety of developmental (e.g., Bayley), cognitive (e.g., Stanford-Binet), neuropsychological (e.g., Purdue Pegboard), family functioning, and physiological indices in order to delineate those factors in the SCD group that were associated with decreased cognitive and academic performance. A unique and important feature of this research was the inclusion of magnetic resonance imaging technology. These techniques made it possible to study in a comprehensive and componential manner the neuroanatomical effects of SCD instead of relying on any single instrument or assessment to document this phenomenon. Goals of this study included the identification of: (a) specific areas of learning deficiencies in children with SCD; (b) the period in which these deficiencies began to occur; and (c) the relationship between types of learning deficits and various outcome measures. In sum, this study helped to determine how these factors interacted and changed over time as the child with SCD matured, the disease fluctuated, and the family and/or the environmental context changed in relation to cognitive development.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Study design
Who may qualify
- Ages
- Up to 100 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2016.
Related trials for Blood Disease
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Active, not recruitingPhase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Blood Disease and Anemia, Sickle Cell, run by National Heart, Lung, and Blood Institute (NHLBI).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 May 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2016.